162 related articles for article (PubMed ID: 11408207)
21. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates.
Millán L; Cerdá P; Rubio MC; Goñi P; Canales M; Capilla S; Oca M; Gómez-Lus R
J Chemother; 2004 Jun; 16(3):230-7. PubMed ID: 15330317
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
Farrell DJ; Morrissey I; Bakker S; Buckridge S; Felmingham D
Antimicrob Agents Chemother; 2004 Aug; 48(8):3169-71. PubMed ID: 15273142
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Rybak MJ; Hershberger E; Moldovan T; Grucz RG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
[TBL] [Abstract][Full Text] [Related]
25. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
27. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).
Ballow CH; Biedenbach DJ; Rossi F; Jones RN;
Braz J Infect Dis; 2002 Jun; 6(3):100-9. PubMed ID: 12144745
[TBL] [Abstract][Full Text] [Related]
28. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin/dalfopristin and linezolid.
Rodriguez-Avial I; Rodriguez-Avial C; Culebras E; Picazo JJ
Int J Antimicrob Agents; 2003 Jun; 21(6):536-41. PubMed ID: 12791466
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Abb J
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
[TBL] [Abstract][Full Text] [Related]
31. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
Giacometti A; Cirioni O; Ghiselli R; Orlando F; Mocchegiani F; Silvestri C; Licci A; De Fusco M; Provinciali M; Saba V; Scalise G
Antimicrob Agents Chemother; 2005 Oct; 49(10):4042-5. PubMed ID: 16189078
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.
Lozniewski A; Lion C; Mory F; Weber M
Pathol Biol (Paris); 2000 Jun; 48(5):463-6. PubMed ID: 10949841
[TBL] [Abstract][Full Text] [Related]
35. Bacteriostatic or bactericidal effect of linezolid against multiresistant Streptococcus pneumoniae.
Malm A; Korona-Głowniak I; Biernasiuk A; Kalasiewicz A; Juda M
New Microbiol; 2008 Jul; 31(3):363-70. PubMed ID: 18843891
[TBL] [Abstract][Full Text] [Related]
36. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
37. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
Gosbell IB; Fernandes LA; Fernandes CJ
Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics.
Samra Z; Ofer O; Shmuely H
Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
40. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]